Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor  by Peltola, Katriina et al.
Pim-1 Kinase Expression
Predicts Radiation Response
in Squamocellular Carcinoma
of Head and Neck and Is
under the Control of Epidermal
Growth Factor Receptor1,2
Katriina Peltola*, Maija Hollmen†,‡,
Sanna-Mari Maula†,§, Eeva Rainio*,
Raija Ristamäki¶, Marjaana Luukkaa¶,
Jouko Sandholm*, Maria Sundvall†,‡,
Klaus Elenius†,‡,¶, Päivi J. Koskinen*,#,
Reidar Grenman‡,** and Sirpa Jalkanen†,§
*Turku Centre for Biotechnology, University of Turku
and Åbo Akademi University, Turku, Finland; †MediCity
Research Laboratory, University of Turku, Turku, Finland;
‡Department of Medical Biochemistry and Genetics,
University of Turku, Turku, Finland; §The National Institute
for Health and Welfare, and Department of Medical
Microbiology, University of Turku, Turku, Finland;
¶Department of Oncology and Radiotherapy, Turku
University Central Hospital, Turku, Finland; #Division of
Genetics and Physiology, Department of Biology,
University of Turku, Turku, Finland; **Department of
Otorhinolaryngology – Head and Neck Surgery,
Turku University Central Hospital, Turku, Finland
Abstract
Pim-1 is an oncogenic serine/threonine kinase with poorly defined function in epithelial cancers. In this study, we
determined 1) associations of Pim-1 expression with clinicopathological parameters including responsiveness to
irradiation in squamocellular cancers of head and neck and 2) how Pim-1 expression is controlled subsequent to
irradiation. Moderate to high expression of Pim-1 correlated to poor response to radiation therapy (P = .003). It
is also associated to the expression of epidermal growth factor receptor (EGFR, P < .0001), which has been shown
to be activated by irradiation. In radioresistant tumors, irradiation promoted nuclear translocation of Pim-1 (P <
.005). When directly testing EGFR dependence of Pim-1 expression, up-regulation and nuclear translocation of
Pim-1 could be induced through stimulation of EGFR with its ligands EGF or transforming growth factor α. Both
ligand- and irradiation-induced changes in Pim-1 expression and localization could be inhibited by the monoclonal
anti-EGFR antibody cetuximab and by the tyrosine kinase inhibitor gefitinib also targeting EGFR. These results sug-
gest that irradiation-induced activation of EGFR upregulates Pim-1, and Pim-1 may be used as a novel predictive
marker of radiation response in patients with squamocellular cancers of head and neck.
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Introduction
The pim-1 gene encodes a serine/threonine kinase that has been im-
plicated in cytokine receptor–initiated signaling as well as in cellular
survival [1,2]. It has also been shown to regulate activities of several
transcription factors and cell cycle regulators [3–8].
The pim-1 gene was originally identified as a proviral integration site
for the Moloney murine leukemia virus [9] and was shown to function
as a proto-oncogene. Alone, pim-1 is only weakly oncogenic, but a
series of studies with transgenic mouse models has demonstrated that
pim-1 can efficiently cooperate with other oncogenes such asmyc family
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members, bcl-2 or gfi-1 in the development of B- or T-cell lymphomas
[10–13]. Elevated levels of pim-1 have also been found in human lym-
phoid and myeloid malignancies [14]. Although recent studies have
identified pim-1 as a prognostic marker for one epithelial cancer type,
prostate cancer [15], its behavior during malignant transformation of
epithelial cells and its correlation to clinicopathological parameters have
remained less well known. Therefore, the purpose of our study was to
analyze the expression of the Pim-1 kinase in squamocellular cancers
of head and neck (HNSCC) to establish a possible association among
the expression status, clinical behavior, and treatment response of the
tumors. The strong association observed between Pim-1 and epidermal
growth factor receptor (EGFR) expression led to further analyses on
regulation of Pim-1 by EGFR triggering.
Materials and Methods
Patients
Seventy-one patients with histopathologically defined HNSCC
treated at the Department of Oncology and Radiotherapy and at
the Department of Otorhinolaryngology – Head and Neck Surgery
at Turku University Hospital were included in the study. The median
age of the study patients was 66 years (ranged from 25 to 97 years) at
the time of diagnosis, representing that of the general population
with HNSCC. The patient characteristics are listed in Table W1, and
their treatments are listed in Table W2. After the follow-up period of
60 months, 23 patients were alive. Twenty-seven died of HNSCC
and 17 died from other reasons. In three cases, the cause of death was
not known, and one patient died of a cancer treatment. Primary diag-
nostic biopsy samples were taken from all 71 primary tumors before
any therapy was given. In addition, surgical samples were taken after
preoperative irradiation from all patients undergoing surgery (n = 52).
The expressions of Pim-1 and EGFR were analyzed in those surgical
samples, which were Pim-1–positive in the primary diagnostic samples
before irradiation.
All tissue sampling and experimental procedures were approved by
the institutional human research committee, and informed consent of
the patients was obtained.
Primary Antibodies
Mouse monoclonal anti–Pim-1 antibody (19F7) raised against a C-
terminal peptide was a kind gift from Dr. Michael Lilly (Loma Linda
University, Loma Linda, CA). This antibody specifically recognizes
Pim-1 but not the other Pim family members. Anti-EGFR (clone 25)
antibody was from Novocastra Laboratories, Ltd. (Newcastle upon
Tyne, United Kingdom) and the monoclonal antibody 3G6 (against
chicken T cells) used as a negative control was made in house.
Histologic Diagnosis and Immunoperoxidase Staining
At the time of diagnosis, histopathological evaluation revealed that
all tumors displayed typical features of squamous cell carcinoma. After
preoperative radiotherapy, tumors were considered to have viable tumor
tissue, if an experienced pathologist observed any well-preserved tumor
tissue histology with mitotic figures. If viable tumor tissue was observed
after preoperative radiotherapy, the tumor was scored as a nonresponder
to irradiation.
The expression level and distribution of Pim-1 and EGFR proteins
were determined using formalin-fixed paraffin-embedded sections
and indirect immunoperoxidase staining method as described [16].
Briefly, sections were stained with primary antibodies followed by
reagents of the Vectastain Elite ABC kit (Vector Laboratories, Inc.,
Peterborough, United Kingdom). 3,3-Diaminobenzidine in Tris-
buffered saline containing 0.03% H2O2 was used as the substrate for
the peroxidase-mediated reaction.
Antibody staining was scored by using a semiquantitative scale com-
bining both intensity and percentage of positive cells. The interexperi-
mental variation in staining intensity was controlled by adjusting the
scoring to the intensity of Pim-1 staining in normal tumor-infiltrating
lymphocytes present in variable numbers in each tumor. Score 0 (neg-
ative) represents practically no Pim-1 or EGFR positivity, whereas
score 3 (strong) was given to samples in which practically all tumor
cells were strongly positive. Score 1 (weak) was given to samples ex-
pressing weakly positive cells comparable to the level of Pim-1 in normal
keratinocytes, and score 2 (moderate) was adjusted to cover the stain-
ing patterns in between 1 and 3 (see also examples in Figure 1). Scoring
was performed by two independent readers. The borderline cases (n = 6)
were jointly reviewed, and a consensus was sought.
Figure 1. Pim-1 protein is overexpressed in a subset of HNSCCs.
(A) Tonsil tissue stained with anti–Pim-1 antibody exhibiting weak
expression of Pim-1 in normal epithelium (E). Some normal lympho-
cytes expressing Pim-1 are pointed out by arrowheads. (B) Staining
of the same sample as in (A) with a negative control antibody. (C)
Moderate expression of Pim-1 in grade 1 carcinoma. (D) Strong ex-
pression of Pim-1 in grade 1 carcinoma. The longer arrows point to
cells with nuclear Pim-1 expression, and the arrowheads point to
cells with prominent cytoplasmic Pim-1 localization. Bar, 50 μm.
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Cells and Cell Lines
HaCaT, a spontaneously transformed human adult epithelial cell
line with full epidermal differentiation capacity, was a kind gift from
Professor N.E. Fusenig (German Cancer Research Centre, Heidelberg,
Germany) [17]. The HNSCC cell lines were established from patients
with cancer of the head and neck region as previously described [18].
Tumor Model
To determine the usability of HNSCC lines in our studies, tumor
nodules were grown in severe combined immunodeficient (SCID)
mice, and their Pim-1 expression was determined. HaCaT cells and five
human HNSCC cell lines were injected subcutaneously into the back
of SCID mice. During the following 25 to 41 days, the tumor nodules
became clearly visible, and the animals were killed. The nodules were
excised, frozen in liquid nitrogen, and prepared for immunofluores-
cence staining. The permission for animal experiments was obtained
from the Ethical Committee of Turku University.
Growth Factors and Inhibitors
Cultured HNSCC cell lines were stimulated with or without 20
and 50 ng/ml EGFR ligands, EGF (Intergen, Edinburgh, United
Kingdom) or transforming growth factor α (TGF-α; R&D, Oxon,
United Kingdom) for 18 or 72 hours. To inhibit EGFR signaling, anti-
EGFR antibody cetuximab (10 nM; Merck, Espoo, Finland) or EGFR
targeting tyrosine kinase inhibitor gefitinib (10 μM; AstraZeneca,
Espoo, Finland) were added together with EGF for 72 hours. A tumor-
promoting agent (TPA), 12-O-tetradecanoyl-phorbol-13-acetate
(15 ng/ml; Sigma-Aldrich, St. Louis, MO), was used as a control. In
the irradiation experiments, cetuximab and gefitinib were administered
24 hours before the irradiation (2Gy), and the stainings for Pim-1 expres-
sion were performed 48 hours after irradiation.
Small Interfering RNA Treatments, Viability Determinations,
and Western Blot Analysis
Monolayers of HNSCC cells were transfected with Oligofectamine
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions
using Dharmacon (Chicago, IL) ON-TARGET plus small interfering
RNA (siRNA) oligonucleotides that were either nontargeting (NT) or
specifically targeted Pim-1 siRNA. Twenty-four hours later, the cells
were irradiated (2 or 3 Gy) and incubated for an additional 48 hours
before the analysis of cell viability. Viability was determined by trypan
blue staining. Ten microscopic fields (magnification, ×400) of each well
were counted for trypan blue–positive cells. In addition, cell death was
determined using flow cytometry. Shortly, tumor cells were collected
in PBS and then treated with hypotonic buffer (1% Triton X-100,
0.05 mg/ml propidium iodide in PBS) for 20 minutes at 4°C. DNA
content was measured using FACSCalibur flow cytometer with Cell-
Quest Pro software (BectonDickinson, CA). Apoptosis analysis was per-
formed using ModFit LT (Verity Software House, Inc., Topsham, ME)
cell cycle modeling software by calculating the subdiploid population.
Silencing of Pim-1 expression was confirmed byWestern blot analysis
and immunofluorescence (as explained in the next section). ForWestern
blot analysis, the cells were lysed, and protein concentrations were mea-
sured. Equal amounts of protein from each sample were separated by
SDS-PAGE, blotted onto polyvinylidene difluoride membrane and
analyzed for Pim-1 expression using anti–Pim-1 antibody (sc-13513,
clone 12H8; Santa Cruz, Heidelberg, Germany) followed by ECL Plus
reagents (GE Healthcare, Helsinki, Finland) and autoradiography.
Immunofluorescence Staining
HaCaT and HNSCC cell lines were grown on coverslips. These
cells were fixed with 4% paraformaldehyde for 20 minutes, treated with
0.2% Nonidet P-40 for 5 minutes and subjected to indirect immuno-
fluorescence staining as described [16] with anti–Pim-1, anti-EGFR, or
the negative control antibody, 3G6 against chicken T cells. Fluorescein
isothiocyanate–conjugated anti–mouse immunoglobulin G (Sigma)
containing 5% of normal human serum was used as a secondary anti-
body. The stainings were analyzed using Olympus 60BX microscope
(Hamburg, Germany). Subcellular localization and Pim-1 positivity
were scored by two independent readers. The intensity scores were as
follows: +, weak; ++, moderate; +++, strong.
Statistical Analyses
Statistical analyses were performed with the SAS Enterprise Guide
2 computer program for the personal computer (SAS Institute, Inc.,
Espoo, Finland). To test the associations between different biological
variables and between the Pim-1 expression and clinicopathological
parameters, χ 2 test was used for trends, the Fisher exact test was used
for categorical variables, and Pearson correlation coefficient test was
used for continuous data. Cumulative survival between the groups for
each variable studied was compared with the log-rank and Wilcoxon
tests. McNemar test was used to analyze the changes in nuclear locali-
zation after radiation therapy.
Results
Pim-1 Expression in HNSCC
Pim-1 protein expression was analyzed by immunoperoxidase stain-
ing in squamocellular epithelium of normal tonsils and in 71 primary
diagnostic biopsy samples of HNSCC (Tables W1 and W2 for patient
characteristics). Pim-1 expression was weak or negative in keratinocytes
of normal tonsil tissues, whereas many of tonsillar lymphocytes ex-
pressed clearly detectable levels of Pim-1 (Figure 1A). Of 71 HNSCCs,
29 (41%) showed weak or negative Pim-1 expression that was com-
parable to Pim-1 expression detected in keratinocytes of normal tonsil
tissue. However, 32 (45%) of 71 HNSCCs expressed moderate levels
of Pim-1, and a strong Pim-1 expression was detected in 10 (14%) of
71 HNSCCs. Thus, the majority (59%) of HNSCC overexpressed
Pim-1when comparedwith the expression level in normal keratinocytes.
In Pim-1–expressing tumors, the intracellular localization of Pim-1 was
heterogenous. Although many cells exhibited nuclear localization of
Pim-1, also cells with cytoplasmic Pim-1 expression were found in each
Pim-1–positive tumor (Figure 1, C and D).
Association of Pim-1 Expression with
Clinicopathological Parameters
Pim-1 expression in primary diagnostic biopsy samples did not cor-
relate with the histological grade of differentiation, sex, age at diagnosis,
tumor size, or presence of lymph node metastases (data not shown).
However, Pim-1 expression showed a trend of association with overall
survival (P = .09; Figure 2A). Tumor size and nodal status were signifi-
cantly associated with survival (P < .05; data not shown). These findings
suggest that, in HNSCC, relatively high Pim-1 expression levels tend
to associate with poor prognosis.
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Pim-1 Expression Is Associated with Poor Response to
Irradiation and Expression of EGFR
The standard treatment regimen for HNSCC in Turku University
Hospital includes initial preoperative radiotherapy followed by surgery
3 weeks later. This provided us with an opportunity to study cellular
and molecular responses to irradiation in the tumor samples removed in
the operation after irradiation. Sixty-four of the HNSCCs examined
were initially subjected to radiotherapy and 52 of them were operated
on. Viable tumor tissue was observed in histological analyses of oper-
ated tumor samples more frequently in tumors with moderate to strong
Pim-1 expression than in tumors with low or no Pim-1 expression (P =
.003). These findings indicate that upregulated expression of Pim-1
associates with poor response to irradiation in HNSCC (Table 1).
Expression of EGFR has previously been linked to radiation resis-
tance in HNSCC [19]. As Pim-1 expression behaved similarly as has
been described for EGFR, we analyzed EGFR expression also in our se-
ries. Sixty-one primary diagnostic biopsy samples and 17 Pim-1–positive
postoperative samples were available for immunohistochemical stain-
ings. One of the primary diagnostic biopsy samples was negative, 26 ex-
pressed low levels, 27 moderate and 7 high levels of EGFR. As expected,
expression levels of EGFR inversely correlated with responsiveness to ir-
radiation (P = .018; Table 1). Furthermore, EGFR expression strongly
associatedwith Pim-1 expression both in primary diagnostic biopsy sam-
ples and in surgical samples taken after irradiation (P < .0001). In con-
trast to Pim-1 and EGFR expression, the classic prognostic parameters
such as tumor size, nodal status, and histological grade did not sig-
nificantly associate with the radiation response (Table 1). However,
favorable response to radiation therapy was significantly associated
with survival (P = .05; Figure 2B). These data indicate that both
Pim-1 and EGFR expression are markers of poor response to irradiation
in HNSCC.
Tumors with Poor Response to Irradiation Demonstrate
Nuclear Localization of Pim-1
Irradiation has been reported to change intracellular localization of
EGFR in radioresistant tumor cells, and it also causes autophosphory-
lation and activation of EGFR [19,20]. Because nuclear localization has
recently been shown to be required for oncogenicity of Pim-1 in Burkitt
lymphoma [21], we wanted to analyze the effects of irradiation on sub-
cellular localization of Pim-1. Therefore, Pim-1 protein expression was
analyzed from 17 surgical samples that included viable radioresistant
tumor tissue after preoperative irradiation. Only patients who had
Pim-1–positive tumor cells in the primary diagnostic biopsy samples
were included in the analysis. Irradiation did not induce any obvious
changes in subcellular localization of Pim-1 in any of those tumors
(9/17), which had prominent nuclear Pim-1 expression already in the
primary diagnostic biopsy sample. By contrast, irradiation induced nu-
clear translocation of Pim-1 immunoreactivity in the rest of the tumors
(8/17) that, before irradiation, demonstrated preferentially cytoplasmic
localization of Pim-1 (P < .005). These data suggest that irradiation in-
duces nuclear translocation of Pim-1 in tumors, which do not respond
well to irradiation.
Ligand-Induced Activation of EGFR Regulates Pim-1
Expression and Subcellular Localization
Our results demonstrated that Pim-1 and EGFR expression associ-
ated with each other in HNSCC. In addition, we showed that both
Pim-1 and EGFR associated with poor response to irradiation and that
Pim-1 was translocated into the nuclei of HNSCC cells after irradiation
in radioresistant tumors. To discriminate whether the expression pat-
terns of EGFR and Pim-1 are simply coincidental or whether these
molecules are involved in the same signaling pathway in HNSCC, we
next studied the putative effects of EGFR activation on Pim-1 expres-
sion and subcellular localization using previously established HNSCC
cell lines expressing Pim-1 and EGFR (Table 2). Although the cell lines
were originally grown from humanHNSCC, we first wanted to validate
the use of these cell lines by testing their capacity to still form tumors
in vivo. The selected cell lines (UT-SCC-12A,UT-SCC-22,UT-SCC-40,
UT-SCC-43A, and UT-SCC-54C; Table 2) represented tumors, which
originated from different anatomical locations, were of different grades
Table 1. Correlations to Radiation Response.
Parameter P
Age .65
Sex .53
Site of primary tumor .98
Tumor size .19
Primary clinical stage .28
Nodal status .50
Histological grade .44
Overall survival .05
EGFR positivity .018
Pim-1 positivity .003
P values in bold face font are statistically significant.
Figure 2. Patients with tumors expressing high levels of Pim-1 tend
to have a poor prognosis, whereas patients with tumors respond-
ing to radiation survive longer. Kaplan-Meier survival curves of
patients categorized according to Pim-1 expression (A) and radiation
response (B) of their tumors.
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and had different intracellular localization of Pim-1 when grown in vitro
(Tables 2 and 3). A spontaneously transformed HaCaT human epithe-
lial cell line with full differentiation potential was used for comparison.
All cell lines were injected subcutaneously into SCID mice. Whereas
HaCaT cells reaggregated and formed small rounded nests with multi-
layered sheaths of keratinocytes, all five HNSCC cell lines grew rapidly
at the injection sites, and the animals had to be killed 25 to 41 days after
injection owing to rapid tumor growth. The expression pattern of Pim-1
in HaCaT cells in vivo was rather diffuse, concentrating mostly in the
cytoplasm (Figure 3A) and resembling Pim-1 expression in cultured
HaCaT cells and in normal skin during keratinocyte differentiation (data
not shown). In all HNSCC cell lines grown in vivo, nuclear Pim-1 ex-
pression was observed (two examples shown in Figure 3A). These find-
ings indicate that the cell lines selected for our analyses reproduced the
same ability to translocate Pim-1 into the nucleus as observed in the clin-
ical HNSCC samples in vivo.
Although it is known that irradiation causes even more long-lasting
internalization of EGFR than EGF [22], it may cause many other ef-
fects as well. Therefore, we used specific EGFR ligands to directly test
whether EGFR activation regulates expression levels or distribution of
Pim-1. The in vitro cultured HNSCC lines were stimulated with EGF
and TGF-α. Treatments with either EGF or TGF-α resulted in the
internalization of EGFR (Figure W1) and in an increase of Pim-1 ex-
pression levels in all HNSCC cell lines (Figure 3B and Table 3). Fur-
thermore, EGF and TGF-α induced translocation of Pim-1 into the
nucleus in 10 of 11 HNSCC lines studied (Figure 3B and Table 3).
Nuclear translocation took place in more than 80% of the cells, both in
confluent and subconfluent cell cultures, indicating that translocation
Table 2. Characteristics of the Patients and Specimens Used to Establish the HNSCC.
Cell Line Sex Primary Tumor TNM Location Specimen Type of Site Grade* Lesion
UT-SCC-8 M Supraglottic larynx T2 N0 M0 Larynx pri G1
UT-SCC-12A F Skin of the nose T2 N0 M0 Skin pri G1
UT-SCC-19A M Glottic larynx T4 N0 M0 Larynx pri G2
UT-SCC-22 M Glottic larynx T1 N0 M0 Larynx rec G2
UT-SCC-24A M Tongue T3 N0 M0 Tongue pri G2
UT-SCC-32 M Tongue T3 N0 M0 Oral tongue pri (per) G1
UT-SCC-38 M Glottic larynx T2 N0 M0 Larynx pri G2
UT-SCC-40 M Tongue T3 N0 M0 Tongue pri G1
UT-SCC-43A F Gingiva of mandible T4 N1 M0 Gingiva of mandible pri G2
UT-SCC-50 M Glottic larynx T2 N0; rT2 N0 Larynx rec G3
UT-SCC-54C F Buccal mucosa Neck met G1
met indicates metastasis; pri, primary tumor; pri (per), primary tumor, persistent after radiotherapy; rec, recurrence.
*Grade of the original tumor.
Table 3. Subcellular Localization of Pim-1 Expression in the HNSCC Cell Lines after Different
EGFR Stimulation and Inhibition Treatments.
Cell Line Treatment
− EGF EGF + Inh* TPA
UT-SCC-8 Double pos†++ More nuclear +++ Double pos++ ND‡
UT-SCC-12A More cytopl§++ Nuclear+++ More cytopl++ More cytopl++
UT-SCC-19A Double pos++ More nuclear+++ Double pos++ ND
UT-SCC-22 Double pos++ Nuclear+++ Double pos++ More cytopl++
UT-SCC-24A Double pos+ Nuclear+/++ Double pos+/++ ND
UT-SCC-32 Double pos++ Nuclear++/+++ Double pos++ Cytopl++
UT-SCC-38 More cytopl+ Nuclear++ Cytopl+ ND
UT-SCC-40 Cytopl+ Cytopl++ Cytopl+ Cytopl+
UT-SCC-43A Double pos++ More nuclear+++ Double pos++ More nuclear++
UT-SCC-50 Double pos++ More nuclear+++ Double pos++ Cytopl++
UT-SCC-54C Double pos++ More nuclear+++ Double pos++ More cytopl+/++
*Inh indicates gefitinib and cetuximab (both treatments were separately combined to the EGF
treatment with comparable results).
†Double positive, comparable level of expression in cytoplasm and nucleus.
‡ND indicates not determined.
§Cytopl indicates cytoplasmic.
Figure 3. TheHNSCC cells form tumors in SCIDmicewithmostly nu-
clear Pim-1 expression, and the nuclear translocation of Pim-1 is fur-
ther promoted by EGFR activation. Cells were stainedwith anti–Pim-1
antibody and analyzed under immunofluorescence microscope. (A)
HaCaT cells (used as controls) show mostly diffuse cytoplasmic
staining (arrowheads), whereas UT-SCC-12A and UT-SCC-22 display
preferentially nuclear Pim-1 expression (arrows). HaCaT cells stained
with a negative control antibody are shown in the inset. Bar, 50μm. (B)
Expression of Pim-1 in cell lines UT-SCC-12A, UT-SCC-22, and UT-
SCC-43A was analyzed after indicated treatments. Arrows indicate
the nuclear translocation of Pim-1. Stainings with a negative control
antibody are shown in the insets. Bar, 20 μm.
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was not cell cycle–dependent. By contrast, nuclear translocation of
Pim-1 was observed in only one HNSCC cell line treated with the
phorbol ester TPA (Table 3), demonstrating specificity of the effect.
The EGF-induced nuclear translocation of Pim-1 in HNSCC cell lines
could be inhibited with an anti-EGFR antibody, cetuximab (Figure 3B)
as well as with EGFR targeting tyrosine kinase inhibitor, gefitinib
(data not shown). These data indicate that ligand-induced activation
of EGFR by EGF or TGF-α is sufficient to induce nuclear transloca-
tion of Pim-1 in HNSCC cell lines.
Irradiation Induces EGFR-Dependent Nuclear Translocation
of Pim-1 and Pim-1 Is Involved in Subsequent Cell Survival
To test whether irradiation causes the nuclear translocation of
Pim-1, we subjected SCC-12, SCC-22, and SCC-43 cell lines to 2 Gy
irradiation that corresponds to the daily dose given to patients. Indeed,
this treatment triggered nuclear localization of Pim-1 that could be in-
hibited by pretreatment with EGFR inhibitors, cetuximab or gefitinib
(examples shown in Figure 4A and the situation without irradiation is
seen in Figure 3B). These data confirm that irradiation can cause nu-
clear translocation of Pim-1 in an EGFR-dependent manner.
Next, we evaluated whether presence of Pim-1 affected the survival
of cancer cells after irradiation. Before irradiation, the cell lines were
treatedwith Pim-1–specific siRNA (Pim-siRNA) orNT control siRNA.
The Pim-siRNA treatment efficiently diminished Pim-1 expression
(Figure 4B), and the cells with the remaining low levels of Pim-1 ex-
pression survived significantly poorer after irradiation than cells treated
with NT siRNA and retaining good Pim-1 expression levels. Trypan
blue and flow cytometric analyses with ModFit program gave com-
parable results. The results with trypan blue are shown in Figure 4B.
These results support the concept that Pim-1 protects the cells from
irradiation damage.
Discussion
Here, we describe that the Pim-1 kinase is overexpressed in malig-
nant keratinocytes in HNSCC. In addition, we demonstrate that
moderate/high Pim-1 expression levels tend to associate with poor prog-
nosis in HNSCC compared with low/negative Pim-1 expression levels.
Importantly, Pim-1 overexpression significantly associates with a poor
response to radiotherapy. Because the classic prognostic markers such
as tumor size, nodal status, or histological grade do not predict response
to radiotherapy, and there are currently no generally accepted clinical
markers predicting radiosensitivity, these results may have clinical
implications. Expression of Pim-1 also significantly associates with ex-
pression of EGFR, which has previously been demonstrated to contrib-
ute to radiation resistance [19].
Myeloid and lymphoid malignancies as well as prostate cancer
often display increased levels of Pim-1 [14,15]. It has been suggested
that Pim-1 overexpression drives genomic instability in early tumors,
whereas advanced tumors may downregulate Pim-1 and thereby sta-
bilize acquired abnormalities [23]. Moreover, Pim-1 has been iden-
tified as a survival factor for myeloid cells deprived of cytokines [1,2]
or subjected to genotoxic stress [24]. Thus, HNSCC cells expressing
excessive amounts of Pim-1 may be protected against cell death and
are thereby also resistant to irradiation. These conclusions are consis-
tent with the enhanced carcinogenesis observed in pim-1 transgenic
mice subjected to irradiation [25].
Owing to heterogeneity in the intracellular localization of Pim-1
protein within individual HNSCC tumors, it was practically impos-
sible to take subcellular localization into consideration when analyz-
ing the primary diagnostic samples. However, we were able to show
that irradiation promoted Pim-1 translocation into the nuclei of
HNSCC cells in radioresistant surgical samples. Furthermore, recent
data by Chiang et al. [26] together with our current data indicate
that Pim-1 is mostly cytoplasmic in cells of normal squamocellular
epithelium such as tonsil and skin, whereas its expression is upregu-
lated and predominantly nuclear in many malignant cells. We assume
that nuclear localization of Pim-1 is required for its full activity, es-
pecially for its ability to regulate several transcription factors and cell
cycle regulators. In accordance, nuclear localization of Pim-1 has
been shown to be necessary for its biological effects in Burkitt lym-
phoma [21].
Enhanced expression of Pim-1 was also detected in HNSCC-derived
cell lines established from the original patient samples when compared
Figure 4. Irradiation induces EGFR-dependent nuclear translocation
of Pim-1, and Pim-1 is involved in subsequent cell survival. (A) Pim-1
expression in UT-SCC-12 and UT-SCC-43 cells 2 days after irradia-
tion without and with pretreatment of cetuximab and gefitinib (UT-
SCC-43). Nuclear staining with 4′, 6-diamidino-2-phenylindole. Some
cells with nuclear Pim-1 expression are pointed out by arrows, and
those with cytoplasmic Pim-1 expression are indicated with arrow-
heads. (B) UT-SCC-12 and UT-SCC-43 cell lines were treated with
Pim-1–specific siRNA or NT siRNA before irradiation. Combined re-
sults of the cell survival after the treatments are presented: n = 3.
The effects of siRNA on Pim-1 expression are shown for SCC-12 in
Western blot and immunofluorescence stainings after 2 Gy irradia-
tionwith anti–Pim-1 antibody followedby fluorescein isothiocyanate–
conjugated second-stage antibody. Closed arrows point to nuclear
Pim-1 positivity in NT siRNA-treated cells, and open arrows point
to dimmer Pim-1 staining both in the cytoplasm and in the nucleus
of partially rounded and detached cells treated with Pim-1 siRNA.
Bar, 20 μm.
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with normal human keratinocytes. Interestingly, as shown by immu-
nofluorescence analyses, Pim-1 expression levels were upregulated by
ligand-induced activation of EGFR. Furthermore, activation of EGFR
efficiently shifted the localization of Pim-1 from the cytoplasm to the
nucleus. Most likely in vivo conditions provide sufficient amounts of
EGFR ligands because in EGFR-expressing HNSCC cell lines grown
as tumors in SCID mice, Pim-1 protein is predominantly nuclear.
Epidermal growth factor receptor is one of the upstream activators
of Signal Transducer and Activator of Transcription 3 and Signal
Transducer and Activator of Transcription 5, and pim-1 is a target gene
for both of them [8,27]. Therefore, these STATs are the prime candi-
dates to mediate the signal from EGFR to Pim-1. On the basis of struc-
tural studies, the Pim-1 kinase is considered to reside in a constitutively
active conformation [28]. When its expression and thereby also activity
is upregulated, Pim-1 promotes progression in the cell cycle and inhi-
bits apoptosis by phosphorylating many key enzymes involved in these
processes [8]. Enhanced EGFR signaling due to elevated EGFR expres-
sion levels is also linked to cell proliferation and survival, leading to tu-
mor progression and decreased survival of patients with HNSCC [29].
Interestingly, irradiation and stress are known to lead to activation and
intracellular translocation of EGFR, and their effects are even more per-
sistent than that caused by EGF [22]. Overexpression and activation of
STAT3 and STAT5 are also common in HNSCC [30], indicating that
perturbations in any of these signaling steps can have similar conse-
quences. In this context, it is interesting to note that inhibition of
EGFR increases intrinsic radiosensitivity of HNSCC cell lines in vitro
[31] and that monoclonal antibody therapy against EGFR improves
locoregional control and survival of patients with head and neck cancer,
when combined with radiotherapy [32,33]. On the basis of the existing
literature and our current findings, we suggest that irradiation causes
activation of EGFR and its simultaneous intracellular translocation
leading to nuclear translocation of Pim-1 and up-regulation through
STAT3/5 as depicted in Figure 5. Thus, the efficacy of therapeutics
targeting EGFR in HNSCC may be due to the inhibition of EGFR-
mediated signals activating and translocating Pim-1.
On the basis of our data, HNSCC patients with tumors expressing
moderate or high levels of Pim-1 may not be primary candidates for
radiation therapy. Nevertheless, in the future, radioresistant HNSCCs
could be targeted with inhibitors against Pim-1. Lead compounds for
developing such inhibitors have already been identified [34]. More-
over, because Pim-1 can receive regulatory signals also through other re-
ceptors besides EGFR and even from cytotoxic drugs such as docetaxel
[35], targeting of EGFR and Pim-1 simultaneously may provide syner-
gistic therapeutic effects when treating primarily radioresistant tumors.
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Table W1. Pretreatment Characteristics of the Patients with HNSCC.
Parameter N %
Sex
M 41 57.8
F 30 42.2
Tumor size
T1 14 19.7
T2 31 43.7
T3 16 22.5
T4 10 14.1
Primary clinical stage
Stage I 11 15.5
Stage II 27 38.0
Stage III 17 23.9
Stage IV 16 22.6
Nodal status
N0 50 70.4
N1 13 18.3
N2 8 11.3
Histological grade
1 35 49.3
2 27 38.0
3 9 12.7
Location
Larynx 2 2.8
Tongue 20 28.2
Other oral cavity 23 32.4
Tonsil 4 5.6
Hypopharynx 12 16.9
Other 10 14.1
Figure W1. Epidermal growth factor receptor is internalized after
treatment with EGF and is inhibited by cetuximab. UT-SCC-43 cell
line was stained after different treatments with the anti-EGFR anti-
body, as indicated in the figure. Note the cell surface localization
on nontreated cells (left panel, pointed out by short arrows), cyto-
plasmic localization after EGF treatment (middle panel, longer ar-
rows), and partial inhibition of internalization in the presence of
cetuximab. Positivity on the cell surface is pointed out by short ar-
rows (right panel). Bar, 20 μm.
Table W2. Treatment and Follow-up Characteristics.
Follow-up time of patients (months)
Median 24
Range 2.0-86
Radiation therapy, n (%)
Preoperative (60-70 Gy) 45 (63.4)
Definitive curative 18 (25.4)
Postoperative 1 (1.4)
Palliative 1 (1.4)
No radiation therapy 6 (8.5)
Surgery, n (%)
Curative 50 (70.4)
Palliative 2 (2.8)
No operation 19 (26.8)
Chemotherapy None
Local recurrence, n (%) 26 (36.6)
Persisting disease, n (%) 13 (18.3)
